FY2027 Earnings Estimate for NKTR Issued By HC Wainwright

Nektar Therapeutics (NASDAQ:NKTR) – Investment analysts at HC Wainwright issued their FY2027 earnings estimates for Nektar Therapeutics in a research report issued on Tuesday, December 16th. HC Wainwright analyst A. He expects that the biopharmaceutical company will post earnings per share of ($7.79) for the year. HC Wainwright currently has a “Buy” rating and a $135.00 target price on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ FY2028 earnings at ($9.93) EPS and FY2029 earnings at ($4.91) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.85) by $1.00. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%. The firm had revenue of $11.79 million for the quarter, compared to analyst estimates of $10.20 million.

A number of other analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nektar Therapeutics in a research note on Monday. Citigroup initiated coverage on shares of Nektar Therapeutics in a research note on Wednesday, November 26th. They set a “buy” rating and a $102.00 target price on the stock. B. Riley upped their target price on shares of Nektar Therapeutics from $85.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, September 23rd. Jefferies Financial Group reissued a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday. Finally, Wall Street Zen lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $111.83.

Nektar Therapeutics Trading Down 3.1%

NASDAQ:NKTR opened at $44.00 on Friday. The stock has a 50 day moving average of $57.72 and a two-hundred day moving average of $39.99. Nektar Therapeutics has a 12 month low of $6.45 and a 12 month high of $66.92. The firm has a market cap of $894.96 million, a P/E ratio of -5.52 and a beta of 1.27.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NKTR. Acadian Asset Management LLC boosted its position in shares of Nektar Therapeutics by 1.4% during the first quarter. Acadian Asset Management LLC now owns 7,301,734 shares of the biopharmaceutical company’s stock worth $4,961,000 after buying an additional 100,645 shares during the period. Gainplan LLC acquired a new position in Nektar Therapeutics during the 2nd quarter worth about $388,000. Nuveen LLC purchased a new position in Nektar Therapeutics during the 1st quarter valued at about $222,000. Fred Alger Management LLC purchased a new position in Nektar Therapeutics during the 1st quarter valued at about $344,000. Finally, Jacobs Levy Equity Management Inc. grew its position in Nektar Therapeutics by 14.5% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 3,007,928 shares of the biopharmaceutical company’s stock valued at $2,045,000 after acquiring an additional 380,967 shares in the last quarter. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Insider Buying and Selling

In other Nektar Therapeutics news, CEO Howard W. Robin sold 2,207 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $54.28, for a total transaction of $119,795.96. Following the completion of the sale, the chief executive officer owned 54,245 shares of the company’s stock, valued at $2,944,418.60. This trade represents a 3.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $54.28, for a total value of $62,801.96. Following the completion of the sale, the insider owned 18,971 shares in the company, valued at $1,029,745.88. This represents a 5.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 3,994 shares of company stock worth $216,794. Company insiders own 5.25% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.